Sign Up Today and Learn More About Roivant Sciences Stock
Invest in or calculate the value of your shares in Roivant Sciences or other pre-IPO companies through EquityZen's platform.
About Roivant Sciences Stock
Founded
2014
Industries
Software, Data and Analytics, Artificial Intelligence
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
Roivant Sciences Press Mentions
Stay in the know about the latest news on Roivant Sciences
Sumitomo Dainippon and Roivant confirm strategic alliance
ThePharmaLetter • Oct 31, 2019
Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma's Transaction with Roivant Sciences
benzinga • Oct 31, 2019
Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
globenewswire • Sep 06, 2019
Axovant sends off its small molecule team with an epilepsy drug and $100M in funding commitments
fiercebiotech • Feb 14, 2019
Investors in Roivant Sciences
Discover investors in Roivant Sciences stock and explore their portfolio companies
Roivant Sciences Management
Leadership team at Roivant Sciences
Co-Founder & Chief Executive Officer
Vivek Ramaswamy
Chief Information Officer
Daniel Rothman
Join now and verify your accreditation status to gain access to:
- Roivant Sciences current valuation
- Roivant Sciences stock price
- Available deals in Roivant Sciences and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Roivant Sciences stock?
Accredited investors can buy pre-IPO stock in companies like Roivant Sciences through EquityZen funds. These investments are made available by existing Roivant Sciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Roivant Sciences stock?
Shareholders can sell their Roivant Sciences stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
